Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Splenic artery infusion chemotherapy as neoadjuvant conversion therapy for pancreatic body/tail cancer
ChiCTR2500107417Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2025
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine + nab-paclitaxel and FOLFIRINOX in pancreatic cancer (PC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: R0 resection rate. Started Jan 2025; status: recruiting.
02
Drugs
gemcitabine + nab-paclitaxelFOLFIRINOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500107417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107417.